PT3385284T - Anticorpos para haptenos de quetiapina e sua utilização - Google Patents

Anticorpos para haptenos de quetiapina e sua utilização

Info

Publication number
PT3385284T
PT3385284T PT181576679T PT18157667T PT3385284T PT 3385284 T PT3385284 T PT 3385284T PT 181576679 T PT181576679 T PT 181576679T PT 18157667 T PT18157667 T PT 18157667T PT 3385284 T PT3385284 T PT 3385284T
Authority
PT
Portugal
Prior art keywords
antibodies
quetiapine haptens
quetiapine
haptens
Prior art date
Application number
PT181576679T
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT3385284T publication Critical patent/PT3385284T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9466—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
PT181576679T 2012-08-21 2013-08-20 Anticorpos para haptenos de quetiapina e sua utilização PT3385284T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261691598P 2012-08-21 2012-08-21

Publications (1)

Publication Number Publication Date
PT3385284T true PT3385284T (pt) 2020-05-20

Family

ID=50148312

Family Applications (3)

Application Number Title Priority Date Filing Date
PT201529740T PT3663317T (pt) 2012-08-21 2013-08-20 Anticorpos para haptenos de quetiapina e sua utilização
PT138309901T PT2888286T (pt) 2012-08-21 2013-08-20 Anticorpos para haptenos de quetiapina e sua utilização
PT181576679T PT3385284T (pt) 2012-08-21 2013-08-20 Anticorpos para haptenos de quetiapina e sua utilização

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT201529740T PT3663317T (pt) 2012-08-21 2013-08-20 Anticorpos para haptenos de quetiapina e sua utilização
PT138309901T PT2888286T (pt) 2012-08-21 2013-08-20 Anticorpos para haptenos de quetiapina e sua utilização

Country Status (11)

Country Link
US (3) US9850318B2 (pt)
EP (3) EP2888286B1 (pt)
JP (2) JP6450314B2 (pt)
CN (2) CN104736564B (pt)
AU (2) AU2013305904B2 (pt)
CA (1) CA2882597C (pt)
ES (3) ES2664952T3 (pt)
HK (1) HK1211959A1 (pt)
PL (3) PL3663317T3 (pt)
PT (3) PT3663317T (pt)
WO (1) WO2014031665A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2933478T3 (es) * 2005-08-03 2023-02-09 Astellas Inst For Regenerative Medicine Métodos mejorados de reprogramación de células somáticas animales
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
EP2888590B1 (en) 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antibodies to olanzapine and use thereof
PL2888284T3 (pl) 2012-08-21 2023-02-27 Janssen Pharmaceutica Nv Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
CN106928369B (zh) 2012-08-21 2021-04-02 奥索临床诊断有限公司 喹硫平的抗体及其用途
ES2664952T3 (es) * 2012-08-21 2018-04-24 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
PL3462173T3 (pl) 2012-08-21 2021-08-16 Janssen Pharmaceutica Nv Przeciwciała przeciwko rysperydonowi i ich zastosowanie
PT2887952T (pt) 2012-08-21 2019-08-30 Janssen Pharmaceutica Nv Anticorpos para haptenos da olanzapina e suas utilizações
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
EP3390455A1 (en) * 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
EP3390449A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica N.V. Antibodies to risperidone and use thereof
CN110938082A (zh) * 2019-10-30 2020-03-31 杭州博拓生物科技股份有限公司 一种奥氮平人工抗原及其制备方法
CN111808046B (zh) * 2020-06-30 2022-11-11 杭州同舟生物技术有限公司 一种喹硫平人工半抗原、人工抗原及其制备方法和应用
CN115073492B (zh) * 2022-08-22 2022-11-18 北京丹大生物技术有限公司 一种奥氮平衍生物抗原、奥氮平抗体及其应用
CN116354904B (zh) * 2023-04-26 2023-08-01 北京丹大生物技术有限公司 一种喹硫平衍生物半抗原、抗原、抗喹硫平抗体及其应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
EP0291194B8 (en) 1987-04-27 2003-10-22 Inverness Medical Switzerland GmbH Immunoassays and devices therefor
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
PT582368E (pt) 1992-05-29 2001-05-31 Lilly Co Eli Derivados de tienobenzodiazepina para o tratamento de doencas de cns
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
CA2192467C (en) 1994-06-10 2009-03-31 Alireza Rezaie Calcium binding recombinant antibody against protein c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US6139800A (en) 1997-06-23 2000-10-31 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
ES2358737T3 (es) * 2002-01-31 2011-05-13 Randox Laboratories Ltd. Inmunógenos, anticuerpos y conjugados para cetamina y sus metabolitos.
US20030202975A1 (en) 2002-02-21 2003-10-30 Tedder Thomas F. Reagents and treatment methods for autoimmune diseases
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2003074787A1 (en) 2002-03-04 2003-09-12 Amcol International Corporation Paper and materials and processes for its production
DE60318030T2 (de) 2002-03-28 2008-04-10 Eli Lilly And Co., Indianapolis Piperazine-substituierte aryl-benzodiazepine und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychosen
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
JP2005538108A (ja) 2002-07-29 2005-12-15 ポトマック， ファーマ， エルエルシー α−２アドレナリン作動性レセプターアンタゴニストと非定型抗精神病薬精神安定薬との抗精神病薬組み合わせ治療および組成物
PT1546134E (pt) 2002-08-05 2007-08-10 Lilly Co Eli ''arilbenzodiazepinas substituídas com piperazina''
NZ568403A (en) 2003-05-09 2009-10-30 Univ Duke CD20-specific antibodies and methods of employing same
BRPI0413555A (pt) * 2003-08-18 2006-10-17 Lundbeck & Co As H composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, método para o tratamento de uma doença, para a fabricação de um composto e para a preparação de composto
DE602004024798D1 (de) 2003-09-23 2010-02-04 Fermion Oy Herstellung von quetiapin
AU2004278414B2 (en) 2003-10-01 2012-05-24 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
CN1870980B (zh) 2003-10-23 2010-06-23 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
CA2548164C (en) * 2003-12-12 2013-10-08 Inverness Medical Switzerland Gmbh Assay kit for detecting analytes of interest in samples
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
EP1748070A4 (en) 2004-04-26 2007-07-18 Takami Matsuyama THERAPEUTIC WITH MONOCLONAL ANTIBODY AGAINST FOLAT RECEPTOR BETA (FR-BETA)
US7087699B2 (en) 2004-05-17 2006-08-08 Acushnet Company Sulfur-containing composition for golf equipment, and method of using same
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
FR2878850B1 (fr) 2004-12-02 2008-10-31 Cis Bio Internat Sa Derives de l'inositol-1-phosphate
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
CN101636182B (zh) 2006-10-25 2013-01-16 雷蒙特亚特特拉维夫大学有限公司 具有谷氨酸nmda活性的新型精神病治疗剂
ES2493166T3 (es) * 2006-11-01 2014-09-11 Ventana Medical Systems, Inc. Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
ES2405364T3 (es) 2006-12-29 2013-05-30 Abbott Laboratories Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
CN100482643C (zh) * 2007-01-19 2009-04-29 中国科学院广州生物医药与健康研究院 一种氨基脲衍生物及其单克隆抗体与应用
CN101091700B (zh) * 2007-07-03 2011-06-08 上海现代药物制剂工程研究中心有限公司 富马酸喹硫平缓控释制剂组合物及其制备用途
EP2198309A1 (en) 2007-09-27 2010-06-23 Novartis Ag Drug monitoring assay
EP3338796A1 (en) * 2008-07-21 2018-06-27 Probiodrug AG Diagnostic antibody assay
AU2009279372A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
EA201100613A1 (ru) 2008-10-14 2011-12-30 Астразенека Аб Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций
JP2012507297A (ja) * 2008-10-29 2012-03-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｅｒｂｂ４遺伝子の多型に基づく精神病及び統合失調症の治療法
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
US8480333B2 (en) 2008-12-26 2013-07-09 Steven Edward DeMay Frame rail assemblies and interlocking frame rail systems
US20100203129A1 (en) * 2009-01-26 2010-08-12 Egalet A/S Controlled release formulations with continuous efficacy
EP3138854B1 (en) 2009-03-10 2022-01-26 Baylor Research Institute Antibodies against cd40
US8715699B2 (en) * 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
LT2544536T (lt) * 2010-03-11 2019-02-25 Kempharm, Inc. Kvetiapino riebalų rūgšties konjugatai, jų gamybos būdas ir panaudojimas
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2011159537A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US8913245B2 (en) 2010-06-29 2014-12-16 Kla-Tencor Corporation System and method for interferometric autofocusing
WO2012003418A2 (en) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine d2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
CN102190724A (zh) * 2011-03-31 2011-09-21 上海大学 十氯酮抗原、抗体及其制备方法
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
MX2015002036A (es) 2012-08-16 2016-01-22 Janssen Pharmaceutica Nv Pirazoles sustituidos como bloqueadores del canal de calcio tipo n.
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
JP6131415B2 (ja) 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． イムノアッセイに使用するためのクエチアピンのハプテン
PL3462173T3 (pl) 2012-08-21 2021-08-16 Janssen Pharmaceutica Nv Przeciwciała przeciwko rysperydonowi i ich zastosowanie
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
ES2701062T3 (es) 2012-08-21 2019-02-20 Janssen Pharmaceutica Nv Haptenos de olanzapina
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
CN106928369B (zh) * 2012-08-21 2021-04-02 奥索临床诊断有限公司 喹硫平的抗体及其用途
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
JP6131500B2 (ja) 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドン及びパリペリドンのハプテン
EP2888590B1 (en) 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antibodies to olanzapine and use thereof
PT2888258T (pt) 2012-08-21 2019-08-21 Janssen Pharmaceutica Nv Hapteno de paliperidona
PL2888284T3 (pl) 2012-08-21 2023-02-27 Janssen Pharmaceutica Nv Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
PT2887952T (pt) 2012-08-21 2019-08-30 Janssen Pharmaceutica Nv Anticorpos para haptenos da olanzapina e suas utilizações
ES2664952T3 (es) * 2012-08-21 2018-04-24 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
EP3390455A1 (en) * 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof

Also Published As

Publication number Publication date
PT2888286T (pt) 2018-05-09
ES2788716T3 (es) 2020-10-22
JP2019073513A (ja) 2019-05-16
EP2888286A4 (en) 2016-03-23
US20180105606A1 (en) 2018-04-19
PL3663317T3 (pl) 2023-06-05
AU2017261579A1 (en) 2017-12-07
JP6637580B2 (ja) 2020-01-29
JP2015529203A (ja) 2015-10-05
CN110054693A (zh) 2019-07-26
WO2014031665A1 (en) 2014-02-27
CN104736564B (zh) 2019-02-05
US20200040107A1 (en) 2020-02-06
CA2882597A1 (en) 2014-02-27
AU2013305904A1 (en) 2015-03-05
US20210017294A9 (en) 2021-01-21
CN104736564A (zh) 2015-06-24
ES2935460T3 (es) 2023-03-07
CA2882597C (en) 2020-04-14
US9850318B2 (en) 2017-12-26
US10465013B2 (en) 2019-11-05
EP2888286A1 (en) 2015-07-01
EP3385284B1 (en) 2020-02-26
AU2013305904B2 (en) 2017-08-17
EP3663317B1 (en) 2022-10-12
AU2017261579B2 (en) 2019-11-07
ES2664952T3 (es) 2018-04-24
PT3663317T (pt) 2023-01-23
EP2888286B1 (en) 2018-02-21
EP3385284A1 (en) 2018-10-10
PL3385284T3 (pl) 2020-09-21
EP3663317A1 (en) 2020-06-10
JP6450314B2 (ja) 2019-01-09
HK1211959A1 (en) 2016-06-03
PL2888286T3 (pl) 2018-07-31
US20140057305A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
HK1211959A1 (en) Antibodies to quetiapine haptens and use thereof
HK1255219A1 (zh) 喹硫平的抗體及其用途
HK1211957A1 (en) Antibodies to risperidone haptens and use thereof
HK1211857A1 (en) Antibodies to olanzapine haptens and use thereof
HK1211955A1 (en) Antibodies to aripiprazole haptens and use thereof
HK1212034A1 (en) Antibodies to risperidone and use thereof
HK1211956A1 (en) Antibodies to paliperidone haptens and use thereof
HK1211931A1 (en) Haptens of quetiapine for use in immunoassays
HK1212033A1 (en) Antibodies to olanzapine and use thereof
HK1211989A1 (en) Antibodies to aripiprazole and use thereof
HK1211958A1 (en) Antibodies to paliperidone and use thereof